How will pharmaceutical companies drive growth in 2019? M&A and ground-breaking therapies are already starting to make waves, says Biotech Analyst Difei Yang.

Senior REITs Analyst Haendel St. Juste sees the potential for solid performance this year, but not all REITs are made the same.

Our therapeutic biotechnology analyst Difei Yang talks about exciting advances in gene therapy that piqued her recent desire to cover the field for investors.

Mizuho’s Cheryl Gilberg sits down with Olympian and Gold Medalist Kerri Strug to talk about her iconic gold medal moment in gymnastics history at the 1996 Olympic Games in Atlanta. Kerri also goes into her life after gymnastics, her work with at-risk youth, and her leadership advice to young women.

The convoluted MLP structure is on its way out and investor confidence in the sector is finally looking up. We take a look at Mizuho Analyst Gabriel Moreen's 2019 outlook.

Mizuho's Senior Restaurant and Protein Analyst Jeremy Scott expects the rising costs of labor to accelerate M&A and company exits.

Heightened trade tensions and shifting demand are taking their toll on the beef and poultry industry. Jeremy Scott, Restaurant and Proteins Analyst, weighs in on 2018 trends and what lies ahead.

Which companies are driving the truly transformational and which will be transitional? And how can institutional investors get in on the ground floor? Our Semiconductors & Automotive Technologies Analyst, Vijay Rakesh, recently convened Mizuho’s 2018 Silicon Valley Seminar to spotlight some of the most promising, privately-held firms.

Mizuho's Senior Healthcare Services Equity Analyst finds a correlation between S&P 500 healthcare indices and Washington gridlock.